Bithalamic gliomas may be molecularly distinct from their unilateral high‐grade counterparts

Bithalamic gliomas are rare cancers diagnosed based on poorly defined radiologic criteria. Infiltrative astrocytomas account for most cases. While some previous studies reported dismal outcomes for patients with bithalamic gliomas irrespective of therapy and histologic grade, others described better prognoses even without anticancer therapy. Little is known about their molecular characteristics. We reviewed clinical, radiologic, and histologic features of patients with bithalamic gliomas treated at our institution over 15 years. Targeted sequencing of mutational hotspots in H3F3A, HIST1H3B, IDH1/2, and BRAF, and genome‐wide analysis of DNA methylation and copy number abnormalities was performed in available tumors. Eleven patients with bithalamic gliomas were identified. Their median age at diagnosis was 4.8 years (range: 1–15.7). Additional involvement of the brainstem, basal ganglia, and cerebral lobes occurred in 11, 9, and 3 cases, respectively. All patients presented with hydrocephalus. Two‐thirds of the patients had a histologic diagnosis of anaplastic astrocytoma. Despite aggressive therapy, our youngest patient, the only one diagnosed before 1 year of age, is the sole long‐term survivor. DNA methylation could be performed in seven tumors, all of which clustered with the RTK I ‘PDGFRA’ subgroup by unsupervised hierarchical analysis of methylation array against a previously published cohort of 59 pediatric high‐grade gliomas. Sequencing of hotspots mutations could be done in 10 tumors, none of which harbored H3F3A p.K27 and/or the respective DNA methylation signature, and any other hotspot mutations. Amplification of MDM4 (n = 2), PDGFRA (n = 2), and ID2 combined with MYCN (n = 1) were observed in 7 tumors available for analysis. In comparison with the previously published experience with unilateral high‐grade thalamic astrocytomas where H3F3A p.K27 was present in two‐thirds of cases, the absence of this molecular subgroup in bithalamic gliomas was striking. This finding suggests that unilateral and bithalamic high‐grade gliomas may represent two distinct molecular entities.

[1]  T. Pietsch,et al.  Management of primary thalamic low-grade glioma in pediatric patients: results of the multicenter treatment studies HIT-LGG 1996 and SIOP-LGG 2004. , 2017, Neuro-oncology practice.

[2]  Arie Perry,et al.  Diffuse Midline Gliomas with Histone H3‐K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations , 2016, Brain pathology.

[3]  Uri Tabori,et al.  Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma , 2016, Acta Neuropathologica Communications.

[4]  T. Pietsch,et al.  LG-06MANAGEMENT OF PRIMARY THALAMIC LOW-GRADE GLIOMA IN PEDIATRIC PATIENTS: RESULTS OF THE MULTICENTER TREATMENT STUDIES HIT-LGG 1996 AND SIOP-LGG 2004 , 2016 .

[5]  Roland Eils,et al.  New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs , 2016, Cell.

[6]  J. Drake,et al.  Pediatric thalamic tumors in the MRI era: a Canadian perspective , 2016, Child's Nervous System.

[7]  Scott N. Hwang,et al.  Gliomatosis cerebri in children shares molecular characteristics with other pediatric gliomas , 2016, Acta Neuropathologica.

[8]  Hai Yan,et al.  The H3.3 K27M mutation results in a poorer prognosis in brainstem gliomas than thalamic gliomas in adults. , 2015, Human pathology.

[9]  L. Sullivan,et al.  A sensitive and specific histopathologic prognostic marker for H3F3A K27M mutant pediatric glioblastomas , 2014, Acta Neuropathologica.

[10]  Rafael A. Irizarry,et al.  Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays , 2014, Bioinform..

[11]  Amar Gajjar,et al.  The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma , 2014, Nature Genetics.

[12]  Liliana Goumnerova,et al.  Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma , 2014, Nature Genetics.

[13]  Kuniaki Saito,et al.  H3F3A K27M mutations in thalamic gliomas from young adult patients. , 2014, Neuro-oncology.

[14]  A. Fontebasso,et al.  Molecular biomarkers in pediatric glial tumors: a needed wind of change , 2013, Current opinion in oncology.

[15]  J. Huse,et al.  Evaluation of Histone 3 Lysine 27 Trimethylation (H3K27me3) and Enhancer of Zest 2 (EZH2) in Pediatric Glial and Glioneuronal Tumors Shows Decreased H3K27me3 in H3F3A K27M Mutant Glioblastomas , 2013, Brain pathology.

[16]  David T. W. Jones,et al.  Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. , 2012, Cancer cell.

[17]  M. Delorenzi,et al.  MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status , 2012, Acta Neuropathologica.

[18]  David T. W. Jones,et al.  Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.

[19]  Li Ding,et al.  Somatic Histone H3 Alterations in Paediatric Diffuse Intrinsic Pontine Gliomas and Non-Brainstem Glioblastomas , 2012, Nature Genetics.

[20]  D. Shaw,et al.  Imaging bithalamic pathology in the pediatric brain: demystifying a diagnostic conundrum. , 2011, AJR. American journal of roentgenology.

[21]  J. Smirniotopoulos,et al.  Bilateral thalamic lesions. , 2009, AJR. American journal of roentgenology.

[22]  Dan Nettleton,et al.  Identification of differentially expressed gene categories in microarray studies using nonparametric multivariate analysis , 2008, Bioinform..

[23]  N. Boddaert,et al.  Thalamic tumors in children: a reappraisal. , 2007, Journal of neurosurgery.

[24]  Cheng Cheng,et al.  Robust estimation of the false discovery rate , 2006, Bioinform..

[25]  R. Riccardi,et al.  Neuroimaging of thalamic tumors in children , 2002, Child’s Nervous System.

[26]  C. Di Rocco,et al.  Bilateral thalamic tumors in children , 2002, Child’s Nervous System.

[27]  Russ B. Altman,et al.  Missing value estimation methods for DNA microarrays , 2001, Bioinform..

[28]  T. Merchant,et al.  Bithalamic Involvement Predicts Poor Outcome among Children with Thalamic Glial Tumors , 1998, Pediatric Neurosurgery.

[29]  J. Monges,et al.  Thalamic tumors in children , 1997, Child's Nervous System.